Navigation Links
Prescient Medical Inc. Featured on FOX Business Network
Date:8/27/2009

DOYLESTOWN, Pa., Aug. 27 /PRNewswire/ -- Prescient Medical Inc. announced that CEO Patricia Scheller, appeared on FOX Business Network (FBN) to discuss the company's groundbreaking products and recent achievement of CE Mark approval for their vProtect(TM) Luminal Shield Stent System.

"The FOX Business News appearance is an important recognition of the increasing awareness of cardiovascular disease," stated Ms. Scheller. Each year, approximately 1.5 million Americans will have a heart attack and 650,000 will not survive, making it the leading cause of death in the US. It is estimated that the costs associated with treating heart attacks in the US are over $80 billion per year, or approximately $54,000 per patient, according to 2007 statistics. In addition to the significant financial expenses, the societal and personal costs of the disease are also substantial. "Our goal at Prescient is to ultimately provide the world's first products to stop heart attacks before they happen," she continued.

Ms. Scheller was featured on the "C-Suite Sit-Down" segment on Monday, August 24, 2009, broadcast at 6:40 AM (EDT) in the United States.

Prescient Medical was founded to commercialize a pioneering suite of diagnostic technologies and protective solutions for people with cardiovascular disease. The Company's mission is to reduce morbidity and mortality from heart attacks. Prescient's product portfolio includes catheter-based devices that will allow interventional cardiologists to more precisely tailor focal treatment according to the unique needs of each patient.

The full interview is available through the following link: http://video.foxbusiness.com/8606056/preve
'/>"/>

SOURCE Prescient Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Momentum Women(TM) Honors Patricia Scheller of Prescient Medical for Commitment to Promoting Cardiovascular Disease Awareness
2. Prescient Medical Receives Frost & Sullivan Product Innovation of the Year Award
3. vProtect Luminal Shield (TM) from Prescient Medical Receives CE Mark
4. MSU engineering team designs innovative medical device
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
7. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
8. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
9. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
10. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
11. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...pellents suspected in birth defect that affects ma...Y, Dec. 2 (HealthDay News) -- Male babies of women...months of pregnancy appear to be at increased risk...s report. , This birth defect, which affects ab...ure shortening of the urethra, the tube that carri...
(Date:12/2/2009)...OR, Mich. Even when women at high-risk of breast ...its of using the drug tamoxifen for prevention, on... Researchers at the University of Michigan Compreh...ed to inform women about the risks and benefits as...d to stop breast cancer from returning and has rec...
(Date:12/2/2009)... NCDecember 2, 2009Ninety-six percent of low-incom...nder-based distrust indicated a strong general fee...s general distrust towards men did not prevent the...tic relationship. Furthermore, the union was often...," despite their prior assertions of distrust and ...
(Date:12/2/2009)...tists may not be able to tell a good book by its c...d book by its smell. In a report in ACS, Analytic...be development of a new test that can measure the ...ocuments based on their smell. The nondestructive ...erve a range of prized paper-based objects, some o...
(Date:12/2/2009)...mpions Biotechnology, Inc. (OTC Bulletin Board: CS... a predictive preclinical platform aimed at accele...oncology drugs, has established an exclusive licen...td., Tel Aviv University,s wholly owned technology...compasses the development and commercialization of...
Breaking Medicine News(10 mins):Health News:High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds 2Health News:Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug 2
...ll gain access to innovative medical, education an...st satellite, radio channel created for medical pr...ug. 27 ReachMD XM 157 announced today a new,strat...ians-in-training., Gary Epstein, CEO of ReachMD, ...
...apeutic Radiology and Oncology has selected renown... 2008 honorary member. Dr. Evans will be recognize...er 23, at 10:00 a.m. during ASTRO,s 50th Annual Me...e original Ronald McDonald House, which opened in ...
...of preterm birth cuts risk in half, study finds , ...agnesium sulfate, given to mothers at risk of pret...eir babies by nearly half, a new study found. , "I...ir child from having cerebral palsy," said study l...
...ated with treating ,wet, form of the eye disease ,...Scientists from the United States and China have i...the onset of severe "dry" macular degeneration, on...n work with both human and mice cells, centers on ...
...CT Corporation,(Nasdaq: DRRX ) today reported tha..., has submitted an Investigational New Drug (IND) ...on (FDA) for an abuse-resistant opioid,pain drug c... Pain Therapeutics, for which King Pharmaceuticals...
...e it or not,women and men have different oral heal...e at different stages throughout their life, inclu...ylvania Dental Association (PDA) offers a reminder...they,need to maintain healthy teeth and gums., Ch...
Other Medicine News:Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 3Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3Health News:DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology 2Health News:DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology 3Health News:What You Need to Know About Women's Oral Health 2
(Date:12/2/2009)... , ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCal...d favorable initial results from the first stage o...e safety and immunogenicity of the company,s 2009 ...vaccine. Novavax is conducting this study in coll...pport registration of the vaccine in Mexico and po...
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/1/2009)... , MONTREAL and DUSSELDORF, Germany, ...eading manufacturer of specialized graphics soluti...mbH is now shipping the Matrox Xenia(TM) Series d...S and Mammography solutions using Fujifilm Synaps... in computer based radiography, offering the world...
Breaking Medicine Technology:NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3FUJIFILM Europe Teams Synapse with Matrox Xenia 2FUJIFILM Europe Teams Synapse with Matrox Xenia 3Wistar Institute team finds key target of aging regulator 48508 1Wistar Institute team finds key target of aging regulator 48508 2CAP Announces Health Care Reform Agenda 48504 1CAP Announces Health Care Reform Agenda 48504 2CAP Announces Health Care Reform Agenda 48504 3FDA Panel Mulls Newer Antipsychotics for Kids 48499 1FDA Panel Mulls Newer Antipsychotics for Kids 48499 2FDA Panel Mulls Newer Antipsychotics for Kids 48499 3FDA Panel Mulls Newer Antipsychotics for Kids 48499 4
...nd Associated Microbial Genomes to Understand and ...e Fuels, Biofertlizers, and Disease Control Soluti...ne Accomplishment for Partners who Announced Compl..., Calif. and KUALA LUMPUR, Malaysia, May 20 Synth... applying genomic-driven commercial solutions to a...
...monstrate that maintenance therapy with RISPERDAL(...RLAT) significantly delayed the time to relapse co...der. Results of the study were presented this week...er is a brain disorder that causes unusual shifts .... It is often characterized by debilitating mood s...
Other Medicine Technology:First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology 2First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: